AMAG Pharmaceuticals
AMAG
AMAG was delisted on the 13th of November, 2020.
187 hedge funds and large institutions have $774M invested in AMAG Pharmaceuticals in 2017 Q3 according to their latest regulatory filings, with 35 funds opening new positions, 68 increasing their positions, 54 reducing their positions, and 20 closing their positions.
75% more first-time investments, than exits
New positions opened: 35 | Existing positions closed: 20
26% more repeat investments, than reductions
Existing positions increased: 68 | Existing positions reduced: 54
7% more funds holding
Funds holding: 174 → 187 (+13)
3% less capital invested
Capital invested by funds: $802M → $774M (-$28M)
76% less call options, than puts
Call options by funds: $3.87M | Put options by funds: $16.4M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CCM
Camber Capital Management
Boston,
Massachusetts
|
+$17.7M |
| 2 |
PP
PDT Partners
New York
|
+$5.47M |
| 3 |
D.E. Shaw & Co
New York
|
+$4.45M |
| 4 |
TAM
Tocqueville Asset Management
New York
|
+$4M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$3.99M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Invesco
Atlanta,
Georgia
|
-$25.5M |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$21.7M |
| 3 |
GAM
Gotham Asset Management
New York
|
-$6.87M |
| 4 |
State Street
Boston,
Massachusetts
|
-$6.1M |
| 5 |
Acadian Asset Management
Boston,
Massachusetts
|
-$6.07M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
201
Creative Planning
Overland Park,
Kansas
| – | -$7K | -400 | Closed |
|
|
TRCT
202
Tower Research Capital (TRC)
New York
| – | -$2K | -106 | Closed |
|
|
GI
203
Gradient Investments
Arden Hills,
Minnesota
| – | -$2K | -100 | Closed |
|
|
VCM
204
Versant Capital Management
Phoenix,
Arizona
| – | +$130 | +7 | +54% |
|
AMAG Hedge Fund Activity: Q3 2017 in Review
187 of the 4,012 institutional investors tracked by Wall St. Rank reported a position in AMAG Pharmaceuticals (AMAG) for Q3 2017, worth a combined $774M — down 3.5% from $802M a quarter earlier.
Buyers outnumbered sellers: 35 funds opened new AMAG positions and 20 closed out — a net gain of 15 holders — while 68 added to existing stakes and 54 trimmed.
The largest buyer was Camber Capital Management, adding an estimated $17.7M. The largest seller was Invesco, cutting an estimated $25.5M.
- 187 institutional investors held AMAG Pharmaceuticals (AMAG) as of Q3 2017, up from 174 in Q2 2017.
- Funds reported $774M of AMAG Pharmaceuticals stock for Q3 2017, down 3.5% quarter-over-quarter.
- 35 funds opened new AMAG Pharmaceuticals positions in Q3 2017 and 20 closed out, a net change of +15 holders.
- The largest AMAG Pharmaceuticals buyer in Q3 2017 was Camber Capital Management, an estimated $17.7M added.
- The largest AMAG Pharmaceuticals seller in Q3 2017 was Invesco, an estimated $25.5M sold.
Based on aggregated 13F filings for Q3 2017.